



UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 1 2011

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 6,740,522. The application was filed on July 27, 2010, under 35 U.S.C. § 156. The application was filed on August 10, 2010, under 35 U.S.C. § 156. Please note that patent term extension applications for U.S. Patent No. 7,097,834 and U.S. Patent No. 7,411,050 for BLA No. BL125320 for the human drug product PROLIA® (denosumab) were filed concurrently, pursuant to the provisions of 37 C.F.R. § 1.785.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).



Mary C. Till  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Associate Commissioner  
for Patent Examination Policy

cc: Charles E. Van Horn  
Finnegan, Henderson, Farabow  
Garrett & Dunner LLP  
901 New York Avenue, NW  
Washington DC 20001

RE: PROLIA® (denosumab)  
Docket No.: FDA-2011-E-0660